You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The efficacy of Epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer’s disease: an overview of pre-clinical studies and translational perspectives in clinical practice
|
|---|---|
| Published in |
Infectious Agents and Cancer, June 2017
|
| DOI | 10.1186/s13027-017-0145-6 |
| Pubmed ID | |
| Authors |
Marco Cascella, Sabrina Bimonte, Maria Rosaria Muzio, Vincenzo Schiavone, Arturo Cuomo |
| Abstract |
Alzheimer's disease (AD) is a neurodegenerative disorder and the most common form of dementia characterized by cognitive and memory impairment. One of the mechanism involved in the pathogenesis of AD, is the oxidative stress being involved in AD's development and progression. In addition, several studies proved that chronic viral infections, mainly induced by Human herpesvirus 1 (HHV-1), Cytomegalovirus (CMV), Human herpesvirus 2 (HHV-2), and Hepatitis C virus (HCV) could be responsible for AD's neuropathology. Despite the large amount of data regarding the pathogenesis of Alzheimer's disease (AD), a very limited number of therapeutic drugs and/or pharmacological approaches, have been developed so far. It is important to underline that, in recent years, natural compounds, due their antioxidants and anti-inflammatory properties have been largely studied and identified as promising agents for the prevention and treatment of neurodegenerative diseases, including AD. The ester of epigallocatechin and gallic acid, (-)-Epigallocatechin-3-Gallate (EGCG), is the main and most significantly bioactive polyphenol found in solid green tea extract. Several studies showed that this compound has important anti-inflammatory and antiatherogenic properties as well as protective effects against neuronal damage and brain edema. To date, many studies regarding the potential effects of EGCG in AD's treatment have been reported in literature. The purpose of this review is to summarize the in vitro and in vivo pre-clinical studies on the use of EGCG in the prevention and the treatment of AD as well as to offer new insights for translational perspectives into clinical practice. |
X Demographics
The data shown below were collected from the profiles of 25 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 6 | 24% |
| Spain | 1 | 4% |
| Korea, Democratic People's Republic of | 1 | 4% |
| United States | 1 | 4% |
| Unknown | 16 | 64% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 24 | 96% |
| Practitioners (doctors, other healthcare professionals) | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 216 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 216 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 37 | 17% |
| Student > Ph. D. Student | 27 | 13% |
| Student > Master | 20 | 9% |
| Researcher | 17 | 8% |
| Student > Postgraduate | 10 | 5% |
| Other | 27 | 13% |
| Unknown | 78 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 32 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 27 | 13% |
| Medicine and Dentistry | 16 | 7% |
| Neuroscience | 14 | 6% |
| Chemistry | 11 | 5% |
| Other | 26 | 12% |
| Unknown | 90 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 45. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 January 2024.
All research outputs
#939,784
of 25,791,949 outputs
Outputs from Infectious Agents and Cancer
#15
of 623 outputs
Outputs of similar age
#19,101
of 330,839 outputs
Outputs of similar age from Infectious Agents and Cancer
#1
of 9 outputs
Altmetric has tracked 25,791,949 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 623 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,839 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them